Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abeona Therapeutics ( (ABEO) ) just unveiled an announcement.
On June 27, 2025, Abeona Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher for $155 million, which was awarded by the FDA in April 2025 following the approval of ZEVASKYN™. This sale significantly boosts Abeona’s financial position, providing approximately $225 million in cash resources as of June 30, 2025, ensuring over two years of operating capital and supporting the company’s growth plans, including the anticipated first treatment with ZEVASKYN in Q3 2025 and projected profitability by early 2026.
The most recent analyst rating on (ABEO) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Abeona Therapeutics stock, see the ABEO Stock Forecast page.
Spark’s Take on ABEO Stock
According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.
Abeona Therapeutics faces substantial financial challenges with no current revenue and ongoing losses, impacting its overall score. However, the promising potential for FDA approvals and significant revenue opportunities from new therapies provide a positive outlook. Despite bullish technical signals, the high RSI suggests caution. The stock’s valuation remains unattractive due to its negative P/E ratio, but strong earnings call projections and adequate cash reserves offer some optimism for future performance.
To see Spark’s full report on ABEO stock, click here.
More about Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company specializing in the development of cell and gene therapies for serious diseases. The company is known for ZEVASKYN™, the first and only autologous cell-based gene therapy approved in the U.S. for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. Abeona also focuses on adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical needs.
Average Trading Volume: 1,862,386
Technical Sentiment Signal: Sell
Current Market Cap: $284.9M
For an in-depth examination of ABEO stock, go to TipRanks’ Overview page.